Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

Oscar Arrieta,Pablo Anaya,Vicente Morales Oyarvide,Laura-Alejandra Ramírez-Tirado,Ana C. Polanco

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

2016

Oscar Arrieta
Pablo Anaya
Vicente Morales Oyarvide
Laura-Alejandra Ramírez-Tirado
Ana C. Polanco

Objective Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin–paclitaxel in Mexican institutions.

Keywords:

non-small cell lung cancer (NSCLC)
Carboplatin/paclitaxel
Carboplatin
Mutation testing
Carcinoma
Paclitaxel
Cost-effectiveness analysis
Medicine
Oncology
Gefitinib
Internal medicine
Quality-adjusted life year
Chemotherapy
Test strategy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations